Treatment Naïve Wet AMD

Adverum – ARTEMIS

In this study, we are recruiting patients with both new onset wet AMD and those who area already on treatment. These are patients who respond to therapy, but unfortunately, need regular injections to prevent worsening of their condition. This study utilizes a novel genetic therapy which codes for the “blueprint instructions” to teach the retinal cells to produce their own anti-VEGF molecule. This allows the eye to be its own factory of medication, thus reducing the need for repeated injections. The genetic therapy is injected into the eye during a one-time intravitreal injection. Initial studies have shown both a favorable efficacy and safety profile. In over 4 years of follow-up, >50% of patients did not need further anti-VEGF injections, and there was >80% reduction in further anti-VEGF injections. In this study, patients will either receive the genetic therapy or Eylea injections. The study will be conducted over a 1-year period. At any point in the study, if a patient is not responding well to therapy and meets rescue criteria, they will be treated with standard of care treatment. We hope this trial will demonstrate that genetic therapies can have a long-lasting effect on the eye and reduce the need for repeated anti-VEGF injections.

For more information, visit adverum.com or connect with one of our clinical coordinators.